Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.

BMC Cancer · 2012 · PMC3480888 · PMID 22839200

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP = 0.14not close (p > 0.1)

Of patients with BM, those with hormone receptor-positive disease lived longer (median 68.7 weeks vs 42.3 weeks), but the difference did not reach statistical significance (P = 0.14; Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.